Cargando…
ODP334 Must we Wait for the Development of Metastasis to be Able to Distinguish Dopamine Resistant Aggressive Prolactinoma from Prolactin Producing Pituitary Carcinomas? Case Report and Literature Review
BACKGROUND: Prolactinomas, the most prevalent type of neuroendocrine disease, account for approximately 40% of all pituitary adenomas. In the vast majority of cases, these are benign tumors with excellent clinical response to medical therapy with dopamine agonist agents such as bromocriptine and cab...
Autores principales: | Rios, Paola, Iragorry, Corina, Jara, Mark, Hannoush, Zeina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625523/ http://dx.doi.org/10.1210/jendso/bvac150.1043 |
Ejemplares similares
-
ODP364 Prolactinomas in men: management challenges
por: Baciu, Ionela, et al.
Publicado: (2022) -
FRI298 Serum Prolactin To Tumor Size Ratio As An Effective Parameter To Accurately Distinguish Prolactinoma From NFPT
por: Mishra, Ipsita, et al.
Publicado: (2023) -
ODP309 Ectopic Cushing's Syndrome: Importance of Methodical Approach to Hide and Seek
por: de Souza, Tamara G, et al.
Publicado: (2022) -
Discordance Between Prolactinoma Size and Prolactin Level: An Unusual Laboratory Finding
por: Dawaher, Wafa, et al.
Publicado: (2021) -
ODP343 Phoenixin as a Novel Autocrine/Paracrine Factor Stimulating Prolactin Secretion and Gene Expression at the Pituitary Level in Fish Model
por: Wong, Anderson O L, et al.
Publicado: (2022)